Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Stock Information for Vistagen Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vistagen Therapeutics Inc.

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
Relmada Therapeutics To Present NDV-01 Data at AUA2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.